Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VisionHealth

- PMLiVE

Boehringer taps Korea’s Bridge for Ofev follow-up

Latest in a string of in-licensing deals

- PMLiVE

Boehringer tests speech as early warning for CNS diseases

Company extends foray into digital health innovation

- PMLiVE

Boehringer bolsters NASH pipeline with $870m Yuhan deal

Strengthens existing relationship

- PMLiVE

FDA fast-tracks Jardiance for heart failure review

Would challenge Novartis' Entresto

- PMLiVE

Sanofi/Regeneron’s Dupixent successor underwhelms in phase 2

Success against placebo, but fails to outperform Dupixent

Patient Story Case Study

Streaming Well

- PMLiVE

Boehringer eyes rare disease use for respiratory blockbuster

Would help support respiratory franchise

- PMLiVE

With Spiriva under pressure, Boehringer moves to bolster pipeline

Forges alliance with PureTech Health

- PMLiVE

Boehringer’s IL-36-targeting drug tackles rare form of psoriasis

Antibody would be first-in-class

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

- PMLiVE

AstraZeneca wins NICE backing for asthma injection

NICE hails 'competitive pharma market'

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links